Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 19 | 2024 | 11701 | 2.320 |
Why?
|
| Tetrazoles | 6 | 2024 | 909 | 2.060 |
Why?
|
| Biphenyl Compounds | 6 | 2024 | 1007 | 1.760 |
Why?
|
| Diuretics | 5 | 2024 | 611 | 1.740 |
Why?
|
| Angiotensin Receptor Antagonists | 7 | 2024 | 1039 | 1.710 |
Why?
|
| Drug Combinations | 6 | 2024 | 2048 | 1.620 |
Why?
|
| Stroke Volume | 16 | 2024 | 5521 | 1.400 |
Why?
|
| Heart Failure, Diastolic | 1 | 2023 | 77 | 0.830 |
Why?
|
| Glomerular Filtration Rate | 3 | 2024 | 2182 | 0.760 |
Why?
|
| Ventricular Function, Left | 7 | 2024 | 3899 | 0.610 |
Why?
|
| Furosemide | 3 | 2023 | 170 | 0.600 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2023 | 152 | 0.570 |
Why?
|
| Benzhydryl Compounds | 4 | 2023 | 917 | 0.540 |
Why?
|
| Syncope | 1 | 2019 | 428 | 0.530 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2023 | 1312 | 0.450 |
Why?
|
| Kidney | 6 | 2024 | 7033 | 0.430 |
Why?
|
| Influenza Vaccines | 3 | 2024 | 767 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 12159 | 0.330 |
Why?
|
| Influenza, Human | 3 | 2024 | 1521 | 0.320 |
Why?
|
| Aftercare | 2 | 2023 | 913 | 0.270 |
Why?
|
| Outpatients | 2 | 2024 | 1598 | 0.260 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 2949 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 3493 | 0.240 |
Why?
|
| Correspondence as Topic | 1 | 2024 | 34 | 0.240 |
Why?
|
| Vaccination | 3 | 2024 | 3369 | 0.220 |
Why?
|
| Hypovolemia | 1 | 2023 | 48 | 0.220 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 153 | 0.210 |
Why?
|
| Cardiac Myosins | 1 | 2023 | 128 | 0.210 |
Why?
|
| Humans | 28 | 2024 | 761208 | 0.190 |
Why?
|
| Fabry Disease | 1 | 2021 | 87 | 0.180 |
Why?
|
| Patient Discharge | 2 | 2023 | 3441 | 0.170 |
Why?
|
| Alberta | 1 | 2019 | 67 | 0.160 |
Why?
|
| Pregnancy Trimesters | 1 | 2019 | 197 | 0.150 |
Why?
|
| Denmark | 3 | 2024 | 770 | 0.150 |
Why?
|
| Sodium | 1 | 2022 | 1589 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1504 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2024 | 64681 | 0.120 |
Why?
|
| Hospitalization | 3 | 2023 | 10707 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2024 | 9319 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2019 | 707 | 0.110 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 1031 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 3702 | 0.100 |
Why?
|
| Cardiology | 1 | 2023 | 1693 | 0.100 |
Why?
|
| Postpartum Period | 1 | 2019 | 1178 | 0.100 |
Why?
|
| Inpatients | 1 | 2023 | 2545 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 3089 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 3200 | 0.090 |
Why?
|
| Heart | 1 | 2023 | 4431 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 2254 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 2247 | 0.080 |
Why?
|
| Apolipoprotein A-I | 1 | 2010 | 299 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2023 | 8479 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 4822 | 0.070 |
Why?
|
| Disease Progression | 1 | 2024 | 13511 | 0.070 |
Why?
|
| Female | 10 | 2024 | 392544 | 0.070 |
Why?
|
| Aged | 6 | 2024 | 169288 | 0.070 |
Why?
|
| Male | 9 | 2024 | 360693 | 0.060 |
Why?
|
| Middle Aged | 6 | 2024 | 220853 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2016 | 3111 | 0.060 |
Why?
|
| Quinazolines | 1 | 2010 | 1371 | 0.060 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 1812 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5842 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 54435 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2016 | 3258 | 0.050 |
Why?
|
| Age Factors | 1 | 2019 | 18384 | 0.050 |
Why?
|
| Obesity | 1 | 2024 | 12939 | 0.050 |
Why?
|
| alpha-Galactosidase | 1 | 2021 | 57 | 0.050 |
Why?
|
| Neprilysin | 1 | 2024 | 478 | 0.050 |
Why?
|
| Incidence | 1 | 2019 | 21365 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 59221 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 24021 | 0.040 |
Why?
|
| Time Factors | 1 | 2019 | 39957 | 0.040 |
Why?
|
| Pregnancy | 1 | 2019 | 29893 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 1115 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 58952 | 0.030 |
Why?
|
| Consensus | 1 | 2023 | 3134 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 221119 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 74239 | 0.020 |
Why?
|
| Echocardiography | 1 | 2024 | 5006 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2023 | 2515 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 80674 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 374 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 81326 | 0.020 |
Why?
|
| Quinazolinones | 1 | 2010 | 221 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2010 | 901 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2010 | 2171 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 2412 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 168079 | 0.020 |
Why?
|
| Adolescent | 2 | 2024 | 88298 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 2393 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 2478 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4851 | 0.010 |
Why?
|
| Quality of Life | 1 | 2023 | 13367 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 10756 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 18926 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 18220 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 39126 | 0.000 |
Why?
|
Concepts
(97)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(29)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_